The company said the site footprint will not expand, but the company will fill in the property with more buildings and equipment. Manufacturing capacity will almost triple there.
Lilly said the new investment will allow it to hire 200 more workers at the complex, including engineers, scientists, and lab technicians, for a total of 900 full-time workers when it is fully operational.
The pharmaceutical weight-loss market is predicted to reach at least $100 billion by 2030, according to Goldman Sachs.
Novartis Manufacturing LLC told a committee of the City-County Council on Monday evening that it plans to spend up to $125 million to construct and equip a 79,000-square-foot-building for radiopharmaceutical manufacturing and distribution on the city’s west side.
Hims can offer the prescription weight-loss drugs because U.S. regulators have rules that allow pharmacies to make copycat versions of drugs in shortage, a practice that’s known as “compounding.”
The roster of radiopharmaceuticals players in the Indianapolis area has surged in the past few years to include some of the world’s leading pharmaceutical companies, attracted by the potential for significant growth.
The U.S. Food and Drug Administration is convening a panel of independent experts on June 10 to discuss donanemab’s safety and effectiveness, including the results in patients in a clinical trial.
Lilly’s newest obesity and diabetes medicines, widely known as GLP-1 drugs, are drawing rave reviews from doctors, researchers and patients for their ability to safely and effectively control blood sugar and take off weight.
Eli Lilly and Novo are leading now, but there are multiple drug candidates waiting in the wings that could disrupt that duopoly in the future.
Doctors and pharmacies have reported huge demand for Mounjaro and Zepbound in recent months, causing widespread shortages of the popular drugs.
The company plans to develop at least 12 buildings totaling more than 1.6 million square feet. The project is expected to anchor the LEAP Research and Innovation District northwest of Lebanon.
Meanwhile, demand for Lilly’s Zephound and Mounjaro is leading to a shortage of the drugs that is expected to last until at least mid-year, the FDA said in an update Wednesday.
The call for additional scrutiny surprised Lilly executives, who noted that it is unusual for such a review to occur after the FDA has given an anticipated date to make a decision on approval. An OK for the drug had been expected this month.
Millions of Americans who have dropped pounds and boosted their health using popular obesity drugs like Wegovy and Eli Lilly and Co.’s Mounjaro and Zepbound are finding out what happens when they stop taking them.
In the past 52 weeks, shares have set new records almost every week, due to investor eagerness over the company’s new drugs for obesity and diabetes, two health conditions that plague America, along with other drugs in the pipeline.
A ransomware gang once thought to have been crippled by law enforcement has snarled prescription processing for millions of Americans over the past week, forcing some to choose between paying prices hundreds or thousands of dollars above their usual insurance-adjusted rates or going without lifesaving medicine.
Simtra BioPharma Solutions on Wednesday announced plans to expand its sterile fill/finish manufacturing campus in Bloomington and add about 130 jobs.
Shares in the Indianapolis-based drugmaker are setting new records almost every day, due to investor excitement over the company’s new drugs for obesity and diabetes, two health conditions that plague America.
The U.S. Food and Drug Administration designated psilocybin as a “breakthrough therapy” for treatment-resistant depression in 2018 and for major depressive disorder in 2019.
In recent weeks, the Indianapolis-based philanthropy has been unveiling a flurry of gifts at the $100 million level or higher.
